Sostenibilidad en la fase preanalítica
Dr. Mads Nybo presents:
- Release Date: 03.03.2025
- Duration: 23 minutes
- Guest: Dr. David Grenache
- Host: Director Global Medical & Clinical Affairs Ana-Maria Šimundić
- Introduction: Dr. David Grenache, now retired, former Chief Scientific Officer at TriCore Reference Labs in Alberquerque, New Mexico, shares his views on glucose stabilization methods with our host Ana-Maria Šimundić.
Tiempos para el Episodio 2
- 00:17 - Presentación de David Grenache
- 02:55 - El reto de la prueba de glucosa radica en su rápido deterioro a menos que pueda procesarse inmediatamente o estabilizarse adecuadamente.
- 04:13 - Cómo intentan los laboratorios estabilizar la glucosa y por qué estos métodos no son perfectos
- 05:56 - ¿Qué hace el tubo VACUETTE® FC Mix de Greiner Bio-One?
- 08:28 - ¿Cómo se procesan las muestras en el laboratorio de TriCore?
- 10:08 - ¿Qué ocurre con el procesamiento de muestras que han tenido que ser transportadas a larga distancia?
- 11:32 - Límites de decisión (umbrales) para el diagnóstico de diabetes mellitus
- 18:22 - ¿Hay que estandarizar las pruebas de glucosa en sangre? ¿Existen directrices?
- 20:00 - ¿Cuál es el potencial de los tubos de citrato aparte de la glucosa?
What You Can't Miss – In a Nutshell
Stabilizing glucose has a great impact on diagnoses rates of diabetes
- Glucose declines rapidly in whole blood - at a rate of 7-8% per hour - so preventing this decline is important for accurate diagnosis of diabetes mellitus
Some stabilization methods are imperfect or impractical
- Sodium fluoride is a commonly used stabilizer, but whilst it inhibits enolase in the glycolytic pathway, other enzymes remain active and continue to metabolize glucose
Using a VACUETTE® FC Mix tube does the job
- FC Mix tubes contain fluoride to inhibit enolase, citric acid to acidify the sample and inhibit other glycolytic enzymes, as well as EDTA that chelates the magnesium.
“And so stabilizing glucose to prevent its decline, has a great impact on those, the incidence of diabetes, diagnoses rates, so stabilizing glucose, to prevent its decline is quite important. ”
Get the latest from our podcast
Disclaimer & Shownotes
The guests interviewed in this podcast share their individual experiences with the use of our or comparable products and/or services. The opinions expressed are those of the interviewee and do not claim to represent the opinions or views of Greiner Bio-One. This information partially reflects the opinions of our customers and/or the experiences of individuals and does not claim to represent the opinions or views of Greiner Bio-One.
Products from Greiner Bio-One should only be used by appropriately trained medical professionals in accordance with the relevant instructions for use (IFU). A list of indications, contraindications, precautions, and warnings can be found in the instructions for use that accompany each product or can be downloaded from our website www.gbo.com (Download Center). For further information, please contact your local Greiner Bio-One distributor or visit our website.
All information is provided without guarantee despite careful processing. Liability, warranty, or guarantee of Greiner Bio-One GmbH is excluded. All rights, errors, and changes are reserved. Unless otherwise stated, Greiner Bio-One GmbH holds all copyrights and/or other (usage) rights in the present documents, especially to trademarks, such as the listed (word-image) marks, logos. Any use, reproduction, or other use of the rights of Greiner Bio-One GmbH is expressly prohibited.
Publisher and editor: Greiner Bio-One GmbH, Bad Haller Str. 32, 4550 Kremsmünster, Austria.
Assiamira Ferrara, Monique M. Hedderson, Charles P. Quesenberry, Joseph V. Selby; Prevalence of Gestational Diabetes Mellitus Detected by the National Diabetes Data Group or the Carpenter and Coustan Plasma Glucose Thresholds. Diabetes Care 1 September 2002; 25 (9): 1625–1630. doi.org/10.2337/diacare.25.9.1625
diabetesjournals.org/care/article/25/9/1625/21728/Prevalence-of-Gestational-Diabetes-Mellitus
